

Special Issue

Covalent Inhibitors as Selective Drug Candidates

Message from the Guest Editors

This Special Issue is addressed to authors who are engaged in designing and testing of covalent enzyme inhibitors or receptor antagonists. Even though ligands that covalently bind to their targets have been present for more than a century, intentionally designing molecules that make such bonds is relatively new for fear of their reactivity and potential adverse effects. Therefore, we invite all authors whose research interests deal with any part of development of covalent ligands, from designing, synthesizing, screening, and QSAR model development for potential drug candidates, to their in vitro and in vivo testing. Paper on finding and exploring new, unidentified binding sites, especially on orphan proteins are highly encouraged.

Guest Editors

Dr. Robert Vianello

Laboratory for the Computational Design and Synthesis of Functional Materials, Division of Organic Chemistry and Biochemistry, Ruđer Bošković Institute, 10000 Zagreb, Croatia

Dr. Hrvoje Rimac

Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia

Deadline for manuscript submissions

closed (31 August 2021)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/71136

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).